Products The first agent in the GLP-1 receptor agonist group to be approved was exenatide (Byetta) in the United States in 2005 and in many countries and the EU in 2006. In the meantime, several other drugs have been registered (see below). These drugs are also known as incretin mimetics. They are commercially available as … GLP-1 Receptor Agonists
Products Lixisenatide was approved as a subcutaneous solution for injection in the EU in 2012, in the United States in 2016, and in many countries in 2017 (Lyxumia). Lixisenatide is also combined with insulin glargine; see iGlarLixi (Suliqua). Structure and properties Lixisenatide is a peptide and GLP1 analog of 44 amino acids that, like exenatide, … Lixisenatide
Products Insulin glargine is commercially available as an injectable (Lantus). It has been approved in many countries since 2002. The biosimilar Abasaglar (LY2963016) was approved in the EU in 2014 and in many countries in 2015. The drugs must be stored between 2 to 8°C in a refrigerator. In 2015, Toujeo was additionally approved in … Insulin Glargine
Products The fixed combination Xultophy was approved in many countries and in the EU in 2014 as an injection solution in a prefilled pen. It was released in the United States in 2016. Structure and properties IDegLira is the name given to the combination of the insulin insulin degludec (IDeg, Tresiba) with the GLP-1 receptor … IDegLira
